Search

Objectives: To identify the factors of poor prognosis of ventilator-associated lung disease (VAP) in order to improve their management., Patients and Method: Prospective, descriptive and analytical study of patients admitted to intensive care at the Angré University Hospital from November 1, 2019 to July 31, 2021 and having presented VAP., Results: We collected 43 patients out of 625 admissions, i.e. 6.88%. The average age was 49.06 years. The sex ratio was 0.38. The main reason for admission was coma with 88.37%. Hypertension and diabetes were the main antecedents. Early VAP accounted for 53.49%. Klebsiella pneumoniae was the main germ. Patients intubated on admission accounted for 79.07%. The average duration of ventilation was 26.95 days and the average duration of hospitalization was 30.8140 days. Probabilistic antibiotic therapy was performed in 75.76% of patients. Mortality was 76.74%. The mortality factors were duration of mechanical ventilation greater than 15 days and age greater than 50 years., Conclusion: Secondary mortality from VAP remains high. The identification of the two prognostic factors should improve the subsequent management of all new cases., (Le comité de rédaction se réserve le droit de renvoyer aux auteurs avant toute soumission à l'avis des lecteurs les manuscrits qui ne seraient pas conformes à ces modalités de présentation. En outre il leur conseille de conserver un exemplaire du manuscrit, des figures et des tableaux.)

Objectives: To identify the factors of poor prognosis of ventilator-associated lung disease (VAP) in order to improve their management., Patients and Method: Prospective, descriptive and analytical study of patients admitted to intensive care at the Angré University Hospital from November 1, 2019 to July 31, 2021 and having presented VAP., Results: We collected 43 patients out of 625 admissions, i.e. 6.88%. The average age was 49.06 years. The sex ratio was 0.38. The main reason for admission was coma with 88.37%. Hypertension and diabetes were the main antecedents. Early VAP accounted for 53.49%. Klebsiella pneumoniae was the main germ. Patients intubated on admission accounted for 79.07%. The average duration of ventilation was 26.95 days and the average duration of hospitalization was 30.8140 days. Probabilistic antibiotic therapy was performed in 75.76% of patients. Mortality was 76.74%. The mortality factors were duration of mechanical ventilation greater than 15 days and age greater than 50 years., Conclusion: Secondary mortality from VAP remains high. The identification of the two prognostic factors should improve the subsequent management of all new cases., (Le comité de rédaction se réserve le droit de renvoyer aux auteurs avant toute soumission à l'avis des lecteurs les manuscrits qui ne seraient pas conformes à ces modalités de présentation. En outre il leur conseille de conserver un exemplaire du manuscrit, des figures et des tableaux.)

Objective: To evaluate the anesthetic practice in the operating theater of gynecological and obstetric emergencies., Material and Method: Prospective, descriptive and analytical study on patients admitted to the operating room for a gynecological and or obstetric emergency over a period of six months., Results: We collected 3,486 patients out of 7,574 admissions, or 46.02%. The average age was 27.3 years with extremes of 15 and 45. SFA was the first operative indication for obstetric emergencies while gynecological emergencies were dominated by first trimester bleeding. 99.39% of the patients benefited from a CPA and 45.40% of them, were classified ASA I u. LAR by spinal anesthesia was the most commonly performed anesthetic regimen. Maternal lethality was 0.005. For the mother, the age group [30-45 years], the provenance, the hemorrhagic syndromes, the ASA III and IV classes, the long delays in transfusion and block management were factors of poor prognosis. (P≤0.05) For the fetus, hemorrhagic syndromes and general anesthesia were factors of poor prognosis. (P ≤ 0.05)., Conclusion: Spinal anesthesia was the most widely used anesthetic regimen., (Le comité de rédaction se réserve le droit de renvoyer aux auteurs avant toute soumission à l'avis des lecteurs les manuscrits qui ne seraient pas conformes à ces modalités de présentation. En outre il leur conseille de conserver un exemplaire du manuscrit, des figures et des tableaux.)

Background: Tranexamic acid decreases total blood loss after total hip arthroplasty (THA). Total blood loss is the sum of external bleeding and bleeding into tissues, i.e., haematomas. Haematomas may cause acute or even chronic postoperative pain., Hypothesis: Tranexamic acid decreases haematomas, thereby diminishing postoperative pain after THA., Methods: In a retrospective matched case-control study, patients receiving tranexamic acid (15 mg/kg, before the incision and again at skin closure) were compared to controls not given tranexamic acid. Matching was on sex, surgeon, and peri-operative analgesics (ketamine, ketoprofen, pregabalin, and nefopam). Standardised protocols were used for anaesthesia, analgesia, and blood sparing. Haematoma volume was computed as the difference between total blood loss (estimated from the erythrocyte counts on days -1 and +5) and measured external blood loss. Patients were monitored from D0 to D7 then interviewed by telephone on D30, D90, and D180. To detect a 30%-decrease in the morphine dose at H24 (criterion 1) and D7 (criterion 2) and a 20% decrease in haematoma volume on D5 (criterion 3), the required numbers of patients were 90, 90, and 77, respectively; therefore, 95 patients were included., Results: Tranexamic acid decreased haematoma volume by 30% (351±254 mL versus 247±189 mL erythrocytes, P=0.002), had no effect on morphine consumption at H24 (12±11 mg versus 14±12 mg, P=0.346), increased morphine consumption on D7 (26±24 mg versus 35±36 mg, P=0.029), and had no effect on long-term pain., Discussion: After THA, tranexamic acid decreases haematoma volume without improving analgesia., Level of Evidence: 3 (case-control study)., (Copyright © 2013. Published by Elsevier Masson SAS.)